Stock Track | Beam Therapeutics Soars on Promising Sickle Cell Therapy Data

Stock Track11-06

Beam Therapeutics, Inc. (BEAM) stock surged 8.23% in pre-market trading on November 6, 2024, after the company reported encouraging initial clinical data from its Phase 1/2 BEACON trial evaluating BEAM-101 for the treatment of sickle cell disease.

The data showed that BEAM-101, an investigational cell therapy administered via hematopoietic stem cell transplantation, achieved robust fetal hemoglobin (HbF) induction of over 60% and reduced sickle hemoglobin (HbS) to less than 40% in patients. This hemoglobin profile mimics that of individuals with sickle cell trait, who are typically asymptomatic.

Furthermore, BEAM-101 demonstrated a favorable safety profile consistent with myeloablative conditioning and stem cell transplant. Notably, the therapy facilitated rapid neutrophil engraftment, with all patients engrafting in under 20 days, potentially leading to shorter hospital stays.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138375859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 19:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138375859","market":"us","top_or_hot":-1,"title":"Stock Track | Beam Therapeutics Soars on Promising Sickle Cell Therapy Data","media":"Stock Track","content":"<p>Beam Therapeutics, Inc. (BEAM) stock surged 8.23% in pre-market trading on November 6, 2024, after the company reported encouraging initial clinical data from its Phase 1/2 BEACON trial evaluating BEAM-101 for the treatment of sickle cell disease.</p>\n\n<p>The data showed that BEAM-101, an investigational cell therapy administered via hematopoietic stem cell transplantation, achieved robust fetal hemoglobin (HbF) induction of over 60% and reduced sickle hemoglobin (HbS) to less than 40% in patients. This hemoglobin profile mimics that of individuals with sickle cell trait, who are typically asymptomatic.</p>\n\n<p>Furthermore, BEAM-101 demonstrated a favorable safety profile consistent with myeloablative conditioning and stem cell transplant. Notably, the therapy facilitated rapid neutrophil engraftment, with all patients engrafting in under 20 days, potentially leading to shorter hospital stays.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Beam Therapeutics Soars on Promising Sickle Cell Therapy Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Beam Therapeutics Soars on Promising Sickle Cell Therapy Data\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-06 19:56 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Beam Therapeutics, Inc. (BEAM) stock surged 8.23% in pre-market trading on November 6, 2024, after the company reported encouraging initial clinical data from its Phase 1/2 BEACON trial evaluating ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BEAM","symbol_name":"Beam Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1138375859","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138375859","pubTimestamp":1730894198,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Beam Therapeutics, Inc.  stock surged 8.23% in pre-market trading on November 6, 2024, after the company reported encouraging initial clinical data from its Phase 1/2 BEACON trial evaluating BEAM-101 for the treatment of sickle cell disease.The data showed that BEAM-101, an investigational cell therapy administered via hematopoietic stem cell transplantation, achieved robust fetal hemoglobin  induction of over 60% and reduced sickle hemoglobin  to less than 40% in patients. This hemoglobin profi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BEAM":"Beam Therapeutics, Inc."},"translate_title":"Beam Therapeutics股票因镰状细胞疗法数据前景看好而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":1},"content_text":"Beam Therapeutics, Inc. (BEAM) stock surged 8.23% in pre-market trading on November 6, 2024, after the company reported encouraging initial clinical data from its Phase 1/2 BEACON trial evaluating BEAM-101 for the treatment of sickle cell disease.\nThe data showed that BEAM-101, an investigational cell therapy administered via hematopoietic stem cell transplantation, achieved robust fetal hemoglobin (HbF) induction of over 60% and reduced sickle hemoglobin (HbS) to less than 40% in patients. This hemoglobin profile mimics that of individuals with sickle cell trait, who are typically asymptomatic.\nFurthermore, BEAM-101 demonstrated a favorable safety profile consistent with myeloablative conditioning and stem cell transplant. Notably, the therapy facilitated rapid neutrophil engraftment, with all patients engrafting in under 20 days, potentially leading to shorter hospital stays.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138375859"}